Current radical mesothelioma treatments include chemotherapy
treatments, radiation treatments, surgical treatments and
experimental therapies and drugs. Research news reports the
limited success of present treatments for Mesothelioma.
Mesothelioma research news indicates that traditional treatments
viz. single or multi-drug chemotherapy has a response rate of
about 20%. Radiation treatments, usually used in conjunction
with surgery or chemotherapy treatments can relieve pain and
shrink tumors, making breathing easier. However, radiation
treatments can also cause severe side effects.
Efforts To Combat Mesothelioma
Mesothelioma can take between ten and sixty years to develop
after inhalation of respirable asbestos fibers, but Mesothelioma
progresses fast. Radical surgeries as mesothelioma treatments
have had limited success. Surgical treatments attempted include
extra-pleural pneumonectomy (EPP) and pleurectomy.
Treatment news indicates that in EPP over 15% patients die soon
after surgery. EPP involves removal of pleura, diaphragm,
pericardium, part of the phrenic nerve and the entire
tumor-affected lung and has to be supported by chemotherapy or
radiation.
The pleurectomy treatments involve removal of the pleura without
removing the whole lung. These treatments are best in patients
with good lung expansion who tend to accumulate fluid. In
combination with radiation pleurectomy is reported in treatment
news to have given 22-month survival in 50% and 24-month
survival in 41% cases in a 27-patient group with mesothelioma of
the epithelial subtype.
Surgical treatments of mesothelioma have not been shown to offer
significant advantages over the limited non-surgical treatments.
Experimental drugs under evaluation include treatments by
Onconase, Lovastatin and an Endostatin and angiostatin
combination.
The Mesothelioma Research Foundation of America is funding
research on mesothelioma cure. The USC Norris Comprehensive
Cancer Center in Los Angeles has completed Phase I Clinical
Trials on a new mesothelioma treatment drug called Veglin.
Phase II Clinical trials of Veglin have begun in July 2004,
opening exciting treatment possibilities for mesothelioma
victims.
About the author:
Jon Butt publishes www.the-mesothelioma-guide.com
treatments, radiation treatments, surgical treatments and
experimental therapies and drugs. Research news reports the
limited success of present treatments for Mesothelioma.
Mesothelioma research news indicates that traditional treatments
viz. single or multi-drug chemotherapy has a response rate of
about 20%. Radiation treatments, usually used in conjunction
with surgery or chemotherapy treatments can relieve pain and
shrink tumors, making breathing easier. However, radiation
treatments can also cause severe side effects.
Efforts To Combat Mesothelioma
Mesothelioma can take between ten and sixty years to develop
after inhalation of respirable asbestos fibers, but Mesothelioma
progresses fast. Radical surgeries as mesothelioma treatments
have had limited success. Surgical treatments attempted include
extra-pleural pneumonectomy (EPP) and pleurectomy.
Treatment news indicates that in EPP over 15% patients die soon
after surgery. EPP involves removal of pleura, diaphragm,
pericardium, part of the phrenic nerve and the entire
tumor-affected lung and has to be supported by chemotherapy or
radiation.
The pleurectomy treatments involve removal of the pleura without
removing the whole lung. These treatments are best in patients
with good lung expansion who tend to accumulate fluid. In
combination with radiation pleurectomy is reported in treatment
news to have given 22-month survival in 50% and 24-month
survival in 41% cases in a 27-patient group with mesothelioma of
the epithelial subtype.
Surgical treatments of mesothelioma have not been shown to offer
significant advantages over the limited non-surgical treatments.
Experimental drugs under evaluation include treatments by
Onconase, Lovastatin and an Endostatin and angiostatin
combination.
The Mesothelioma Research Foundation of America is funding
research on mesothelioma cure. The USC Norris Comprehensive
Cancer Center in Los Angeles has completed Phase I Clinical
Trials on a new mesothelioma treatment drug called Veglin.
Phase II Clinical trials of Veglin have begun in July 2004,
opening exciting treatment possibilities for mesothelioma
victims.
About the author:
Jon Butt publishes www.the-mesothelioma-guide.com
No comments:
Post a Comment